Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Tumor in the Crossfire: Inhibiting TGF-β to Enhance Cancer Immunotherapy

BioDrugs(2022)10.1007/s40259-022-00521-1Source: DataRank Database

Tumor in the Crossfire: Inhibiting TGF-β to Enhance Cancer Immunotherapy is a research paper published in BioDrugs (2022). On theSindex it has a DataRank of 0. It has been cited 58 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access58 citations

Download PDF

Cite:

Linked data & code

gen nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 3.93)OA: hybridTopics (32)IDs (PubMed, PMC, OpenAlex)Annotations (3)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (2)

James L. Gulley ORCID,Nicholas Tschernia ORCID

Live enrichment

PubMed:35353346 PMC:PMC8986721 OpenAlex:https://openalex.org/W4220727783

National Cancer Institute

Grant: ZIA BC 010945

Intramural NIH HHS

Grant: Z01 BC010945

FWCI

3.93

Citation Percentile

1.0%

Citation Trend

2022

2023

2024

2025

2026

hybridLicense: cc-by-nc

journalhttps://link.springer.com/content/pdf/10.1007/s40259-022-00521-1.pdf

HYBRIDhttps://link.springer.com/content/pdf/10.1007/s40259-022-00521-1.pdf

publisherhttps://link.springer.com/content/pdf/10.1007/s40259-022-00521-1.pdf

publisherhttps://link.springer.com/article/10.1007/s40259-022-00521-1/fulltext.html

journalhttps://doi.org/10.1007/s40259-022-00521-1

Fields of Study

TGF-β signaling in diseasesCancer Immunotherapy and BiomarkersCancer Cells and MetastasisMedicineBiology

MeSH Terms

Immune Checkpoint InhibitorsAntibodies, MonoclonalCarcinoma, Non-Small-Cell LungHumansImmunologic FactorsImmunotherapyLung NeoplasmsRecombinant Fusion ProteinsTransforming Growth Factor betaTransforming Growth Factor beta1Tumor MicroenvironmentB7-H1 Antigen

Keywords

ImmunotherapyMonoclonal antibodyImmune systemCancer researchTumor microenvironmentImmune checkpointMedicineCancer immunotherapyImmunologyCancerAntibodyIpilimumabCytokineBiologyInternal medicine

Sustainable Development Goals

SDG 0: Good health and well-being